Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Dignass, Axel; Stoynov, Simeon; E Dorofeyev, Andrey; A Grigorieva, Galina; Tomsová, Eva; Altorjay, István; Tuculanu, Daniel; Bunganič, Ivan; Pokrotnieks, Juris; Kupčinskas, Limas; Dilger, Karin; Greinwald, Roland; Mueller, Ralph; Budenofalk Study Group, International

doi:10.1016/j.crohns.2014.01.021

Public

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Shared by NobleBlocks on Sep 1, 2014 • 12:00 AM UTC

Authors:

Axel Dignass

Simeon Stoynov

Andrey E Dorofeyev

Abstract

BACKGROUND: Oral budesonide 9 mg/day represents first-line treatment of mild-to-moderately active ileocolonic Crohn's disease. However, there is no precise recommendation for budesonide dosing due to lack of comparative data. A once-daily (OD) 9 mg dose may improve adherence and thereby efficacy. ME...

Subject

Adherence

Budesonide

Clinical remission

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!